STOCK TITAN
  1. Home
  2. Sec-filings
  3. TARS
  4. [Form 4] Tarsus Pharmaceuticals, Inc. Insider Trading Activity

Tarsus Pharmaceuticals (TARS) director receives RSU and stock option grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Goodrich Katherine reported acquisition or exercise transactions in this Form 4 filing.

Tarsus Pharmaceuticals director Katherine Goodrich received new equity awards as part of her non-employee director compensation. She was granted 2,417 restricted stock units, each representing one share of common stock, and stock options for 3,837 shares with a strike price of $64.34. Both the RSUs and options vest in full one year after the June 25, 2026 grant date, contingent on her continued board service.

Positive

  • None.

Negative

  • None.
Insider Goodrich Katherine
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 3,837 $0.00 --
Grant/Award Restricted Stock Units 2,417 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 3,837 shares (Direct, null); Restricted Stock Units — 2,417 shares (Direct, null)
Footnotes (1)
  1. Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
RSU grant size 2,417 units RSUs granted June 25, 2026, one-year cliff vesting
Stock options granted 3,837 options Annual non-employee director option grant, June 25, 2026
Option exercise price $64.34 per share Conversion or exercise price for 3,837 underlying common shares
Vesting period 1 year Both RSUs and options vest on one-year anniversary of grant
Post-grant RSU holdings 2,417 RSUs Total RSUs following the reported acquisition transaction
Post-grant option holdings 3,837 options Total options following the reported acquisition transaction
Restricted Stock Unit ("RSU") financial
"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock."
non-employee director financial
"Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders."
Stock Option (right to buy) financial
"Stock Option (right to buy) with a conversion or exercise price of 64.3400."
annual meeting of stockholders financial
"Granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Goodrich Katherine
(Last)(First)(Middle)
C/O TARSUS PHARMACEUTICALS, INC.
17700 LAGUNA CANYON ROAD, FLOOR 4
(Street)
IRVINE CALIFORNIA 92618
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$64.3406/25/2026A3,837 (1)06/24/2036Common Stock3,837$03,837D
Restricted Stock Units(2)06/25/2026A2,417 (3) (3)Common Stock2,417$02,417D
Explanation of Responses:
1. Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
3. RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
Remarks:
/s/ Scott Sieckert, Attorney-in-Fact06/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did Tarsus Pharmaceuticals (TARS) director Katherine Goodrich receive?

Director Katherine Goodrich received 2,417 restricted stock units and stock options covering 3,837 shares of Tarsus Pharmaceuticals common stock. These awards are part of her compensation for serving as a non-employee director following the company’s 2026 annual meeting of stockholders.

When do Katherine Goodrich’s new Tarsus Pharmaceuticals equity awards vest?

Both the restricted stock units and stock options granted to Katherine Goodrich vest in full on the one-year anniversary of the June 25, 2026 grant date. Vesting is conditioned on her continuous service as a non-employee director on Tarsus Pharmaceuticals’ board during that period.

What is the exercise price of Katherine Goodrich’s Tarsus Pharmaceuticals stock options?

Katherine Goodrich’s stock options have a conversion or exercise price of $64.34 per share for 3,837 underlying common shares. These options were granted as her annual non-employee director option award at the time of Tarsus Pharmaceuticals’ 2026 annual stockholder meeting.

How many Tarsus Pharmaceuticals shares could Katherine Goodrich eventually receive from her RSUs?

Katherine Goodrich’s 2,417 restricted stock units each represent a contingent right to receive one share of Tarsus Pharmaceuticals common stock. If vesting conditions are met after one year of service, she would receive 2,417 common shares from this RSU grant.

Are Katherine Goodrich’s Tarsus Pharmaceuticals equity awards open-market purchases or compensation grants?

The reported transactions are compensation-related grants, not open-market purchases. Both the restricted stock units and the 3,837-share stock option award were granted in connection with Katherine Goodrich’s service as a non-employee director at the company’s 2026 annual stockholder meeting.

Does the Form 4 show any stock sales by Katherine Goodrich at Tarsus Pharmaceuticals?

The Form 4 does not report any stock sales by Katherine Goodrich. It only shows two acquisition transactions coded as grants: 2,417 restricted stock units and stock options for 3,837 shares, both awarded as part of her non-employee director compensation package.